ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.37 -1.35%

-$0.02 today

Market cap
$192.71M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.17M

Average 1.68M

Income Statement

Follow revenue through to earnings.

Revenue

$81.36M

FY 2025 · Annual

+14.9% YoY

Operating Income

-$108.38M

FY 2025 · Annual

Net Income

-$142.62M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.92M209.91M69.56M70.84M81.36M
Cost of Revenue1.39M3.3M2.53M5.95M7.67M
Gross Profit32.52M206.61M67.03M64.89M73.68M
Gross Margin95.9%98.4%96.4%91.6%90.6%
Research & Development158M186.46M127.13M109.63M104.01M
Selling, General & Admin136.24M143.49M105.89M85.91M(6.82M)
Operating Expenses294.24M329.95M233.02M195.54M182.06M
Depreciation & Amortization2.63M2.39M3.27M3.28M1.88M
EBITDA(230.54M)(107.7M)(145.83M)(102.65M)(89.27M)
EBITDA Margin-679.7%-51.3%-209.6%-144.9%-109.7%
Operating Income(261.72M)(123.34M)(165.99M)(130.65M)(108.38M)
Operating Margin-771.6%-58.8%-238.6%-184.4%-133.2%
Interest Income66K2.57M10.54M12.27M8.81M
Interest Expense18.34M36.73M46.33M50.21M51.63M
Other Income / Expenses10.22M(33.56M)(34.96M)(27.03M)(34.4M)
Income Before Tax(251.51M)(156.9M)(200.95M)(157.68M)(142.78M)
Pre-Tax Margin-741.5%-74.7%-288.9%-222.6%-175.5%
Income Tax Expense(21.48M)227K39.11M166K(157K)
Net Income(230.03M)(157.13M)(240.05M)(157.85M)(142.62M)
Net Margin-678.2%-74.9%-345.1%-222.8%-175.3%
EPS (Basic)(3.00)(1.99)(2.94)(1.62)(1.12)
EPS (Diluted)(3.00)(1.99)(2.94)(1.62)(1.12)
Weighted Avg Shares76.75M78.15M81.71M97.16M127.07M
Weighted Avg Shares (Diluted)76.75M78.15M81.71M97.16M127.07M

ADCT Earnings Waterfall · TTM

NYSE:ADCT · Revenue to Net Income

Key Ratios

EPS$-1.05
Gross Margin90.9%
Net Margin-184.0%
P/E Ratio-7.4
P/S Ratio25.0

Analysis

$79.2M of revenue converted into -$137.0M of net income for the selected period. Gross margin is 90.9% and net margin is -184.0%, showing how much revenue survives after costs and taxes. EPS is $-1.05, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
S-3S-3 filingNov 10, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportNov 4, 2026

How much revenue does ADCT generate?

ADC Therapeutics S.A. (ADCT) reported $81.36M of revenue in fiscal 2025.

Is ADCT profitable?

ADC Therapeutics S.A. (ADCT) reported -$142.62M of net income, with a net margin of -175.3%.